We now report, in both human NSCLC tumours and murine B16F10 melanoma, that Nrp-1 delineates a particular subset of CD8+ TIL, enriched with tumour antigen-specific T lymphocytes, and also expressing high levels of the PD-1 inhibitory receptor. Here, CD8A is linked to melanoma.